APA (7th ed.) Citation

FJE, L., D, B., & NP, v. E. (2017). Fasting conditions in clinical oncology trials and drug labelling - Authors' reply. The Lancet. Oncology, 18(9), e507. https://doi.org/10.1016/S1470-2045(17)30599-5

Chicago Style (17th ed.) Citation

FJE, Lubberman, Burger D, and van Erp NP. "Fasting Conditions in Clinical Oncology Trials and Drug Labelling - Authors' Reply." The Lancet. Oncology 18, no. 9 (2017): e507. https://doi.org/10.1016/S1470-2045(17)30599-5.

MLA (9th ed.) Citation

FJE, Lubberman, et al. "Fasting Conditions in Clinical Oncology Trials and Drug Labelling - Authors' Reply." The Lancet. Oncology, vol. 18, no. 9, 2017, p. e507, https://doi.org/10.1016/S1470-2045(17)30599-5.